Literature DB >> 31127940

Understanding the Profile of Cancer-Related Cognitive Impairments: A Critique of Meta-Analyses.

Todd S Horowitz, Melissa Treviño, Ingrid M Gooch, Korrina A Duffy.   

Abstract

A large body of evidence indicates that cancer survivors who have undergone chemotherapy have cognitive impairments. Substantial disagreement exists regarding which cognitive domains are impaired in this population. We suggest that is in part due to inconsistency in how neuropsychological tests are assigned to cognitive domains. The purpose of this paper is to critically analyze the meta-analytic literature on cancer-related cognitive impairments (CRCI) to quantify this inconsistency. We identified all neuropsychological tests reported in seven meta-analyses of the CRCI literature. Although effect sizes were generally negative (indicating impairment), every domain was declared to be impaired in at least one meta-analysis and unimpaired in at least one other meta-analysis. We plotted summary effect sizes from all the meta-analyses and quantified disagreement by computing the observed and ideal distributions of the one-way χ2 statistic. The actual χ2 distributions were noticeably more peaked and shifted to the left than the ideal distributions, indicating substantial disagreement among the meta-analyses in how neuropsychological tests were categorized to domains. A better understanding of the profile of impairments in CRCI is essential for developing effective remediation methods. To accomplish this goal, the research field needs to promote better agreement on how to measure specific cognitive functions. Published by Oxford University Press 2019. This work is written by US Government employees and is in the public domain in the US.

Entities:  

Mesh:

Year:  2019        PMID: 31127940      PMCID: PMC6792125          DOI: 10.1093/jnci/djz100

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  40 in total

1.  Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen.

Authors:  Steven A Castellon; Patricia A Ganz; Julienne E Bower; Laura Petersen; Laura Abraham; Gail A Greendale
Journal:  J Clin Exp Neuropsychol       Date:  2004-10       Impact factor: 2.475

2.  Discrepancy between subjective and objective measures of cognitive impairment in patients with rheumatoid arthritis.

Authors:  Bo Young Yoon; Joo-Hyun Lee; So Young Shin
Journal:  Rheumatol Int       Date:  2017-09-04       Impact factor: 2.631

Review 3.  Cognitive impairment in breast cancer survivors treated with chemotherapy depends on control group type and cognitive domains assessed: A multilevel meta-analysis.

Authors:  Lori J Bernstein; Graham A McCreath; Zahra Komeylian; Jill B Rich
Journal:  Neurosci Biobehav Rev       Date:  2017-10-29       Impact factor: 8.989

Review 4.  The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature.

Authors:  Marina G Falleti; Antonietta Sanfilippo; Paul Maruff; LeAnn Weih; Kelly-Anne Phillips
Journal:  Brain Cogn       Date:  2005-06-21       Impact factor: 2.310

5.  A Call for a Neuroscience Approach to Cancer-Related Cognitive Impairment.

Authors:  Todd S Horowitz; Jerry Suls; Melissa Treviño
Journal:  Trends Neurosci       Date:  2018-06-12       Impact factor: 13.837

6.  Cancer treatment and survivorship statistics, 2016.

Authors:  Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-06-02       Impact factor: 508.702

Review 7.  Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative.

Authors:  Cameron S Carter; Deanna M Barch
Journal:  Schizophr Bull       Date:  2007-07-14       Impact factor: 9.306

Review 8.  Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?

Authors:  Jeanne S Mandelblatt; Arti Hurria; Brenna C McDonald; Andrew J Saykin; Robert A Stern; John W VanMeter; Meghan McGuckin; Tiffani Traina; Neelima Denduluri; Scott Turner; Darlene Howard; Paul B Jacobsen; Tim Ahles
Journal:  Semin Oncol       Date:  2013-12       Impact factor: 4.929

9.  A meta-analysis of cognitive impairment following adult cancer chemotherapy.

Authors:  Oana C Lindner; Bob Phillips; Martin G McCabe; Andrew Mayes; Alison Wearden; Filippo Varese; Deborah Talmi
Journal:  Neuropsychology       Date:  2014-03-17       Impact factor: 3.295

Review 10.  Cancer- and cancer treatment-associated cognitive change: an update on the state of the science.

Authors:  Tim A Ahles; James C Root; Elizabeth L Ryan
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

View more
  5 in total

1.  Screening recall in older cancer survivors detects differences in balance and mobility.

Authors:  Jennifer Blackwood; Robert Sweeney; Kateri Rybicki
Journal:  Support Care Cancer       Date:  2021-11-23       Impact factor: 3.603

2.  Pre-Surgery Demographic, Clinical, and Symptom Characteristics Associated with Different Self-Reported Cognitive Processes in Patients with Breast Cancer.

Authors:  Yu-Yin Allemann-Su; Marcus Vetter; Helen Koechlin; Steven M Paul; Bruce A Cooper; Kate Oppegaard; Michelle Melisko; Jon D Levine; Yvette Conley; Christine Miaskowski; Maria C Katapodi
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

3.  Protective Effects of APOE ε2 Genotype on Cognition in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study.

Authors:  Kathleen Van Dyk; Xingtao Zhou; Brent J Small; Jaeil Ahn; Wanting Zhai; Tim Ahles; Deena Graham; Paul B Jacobsen; Heather Jim; Brenna C McDonald; Kelly Nudelman Holohan; Sunita K Patel; G William Rebeck; James C Root; Andrew J Saykin; Harvey Jay Cohen; Jeanne S Mandelblatt; Judith E Carroll
Journal:  JNCI Cancer Spectr       Date:  2021-01-27

4.  How do we measure attention? Using factor analysis to establish construct validity of neuropsychological tests.

Authors:  Melissa Treviño; Xiaoshu Zhu; Yi Yi Lu; Luke S Scheuer; Eliza Passell; Grace C Huang; Laura T Germine; Todd S Horowitz
Journal:  Cogn Res Princ Implic       Date:  2021-07-22

5.  Neurocognitive Effects of Chemotherapy for Colorectal Cancer: A Systematic Review and a Meta-Analysis of 11 Studies.

Authors:  Soo Young Hwang; Kwanghyun Kim; Byeonggwan Ha; Dongkyu Lee; Seonung Kim; Seongjun Ryu; Jisu Yang; Sun Jae Jung
Journal:  Cancer Res Treat       Date:  2021-03-17       Impact factor: 4.679

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.